What are the differences between CAR T-cell therapy and bispecific antibodies?

preview_player
Показать описание
In this week’s #AskDrDurie, myeloma expert Dr. Brian G.M. Durie discusses the main differences between the CAR T cells and bispecific monoclonal antibodies.

The BOTTOM LINE: Discuss with your doctor to decide which treatment is available and appropriate for you.
_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Find us online:

Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.
Рекомендации по теме
Комментарии
Автор

Have a question? The IMF's InfoLine team consistently provides callers with the best information about multiple myeloma in a caring and compassionate manner.


800-452 CURE (2873)
US & Canada

1-818-487-7455
Worldwide

IMFMyeloma